Loading...
Loading...

Go to the content (press return)

Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)

Author
Mothe, B.; Manzardo, C.; Sanchez-Bernabeu, A.; Coll, P.; Morón, S.; Puertas, M.; Rosas, M.; Corbasí, P.; Escrig, R.; Perez, N.
Type of activity
Journal article
Journal
EClinicalMedicine
Date of publication
2019-06
Volume
11
First page
65
Last page
80
DOI
10.1016/j.eclinm.2019.05.009
URL
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(19)30087-2/fulltext Open in new window
Abstract
Background: Strong and broad antiviral T-cell responses targeting vulnerable sites of HIV-1 will likely be a criticalcomponent for any effective cure strategy.Methods:BCN01 trial was a phase I, open-label, non-randomized, multicenter study in HIV-1-positive individualsdiagnosed and treated during early HIV-1 infection to evaluate two vaccination regimen arms, which differed inthe time (8 versus 24 week) between the ChAdV63.HIVconsv prime and MVA.HIVconsv boost vaccinations. Theprimary outcome wa...
Group of research
GRBIO - Biostatistics and Bioinformatics Research Group

Participants

  • Mothe, Beatriz  (author)
  • Manzardo, Christian  (author)
  • Sanchez-Bernabeu, Alvaro  (author)
  • Coll, Pep  (author)
  • Morón López, Sara  (author)
  • Puertas Castro, Maria C.  (author)
  • Rosas Umbert, Miriam  (author)
  • Corbasí, Patricia  (author)
  • Escrig, Roser  (author)
  • Perez Alvarez, Nuria  (author)